

Sample Hospital Setting Billing UB-04

1 Hospital Name One Hospital Place City, State 00000		2 Pay - To Name Pay - To Address (if different from billing provider in FL1)		3a PAT. CNTL. # 3b MED. REC. #	4 TYPE OF BILL	
8 PATIENT NAME		9 PATIENT ADDRESS		5 FED. TAX NO.		6 STATEMENT COVERS PERIOD FROM THROUGH
10 BIRTHDATE	11 SEX	12 DATE	13 HR	14 TYPE	15 SRC	16 DHR
17 STAT		18		19		20
21		22		23		24
25		26		27		28
29 ACCT STATE		30		31		32
33 OCCURRENCE DATE	34 CODE	35 OCCURRENCE DATE	36 CODE	37 OCCURRENCE DATE	38 CODE	39
40		41		42		43
44		45		46		47
48		49		50		51
52		53		54		55
56		57		58		59
60		61		62		63
64		65		66		67
68		69		70		71
72		73		74		75
76		77		78		79
80		81		82		83
84		85		86		87
88		89		90		91
92		93		94		95
96		97		98		99
100		101		102		103
104		105		106		107
108		109		110		111
112		113		114		115
116		117		118		119
120		121		122		123
124		125		126		127
128		129		130		131
132		133		134		135
136		137		138		139
140		141		142		143
144		145		146		147
148		149		150		151
152		153		154		155
156		157		158		159
160		161		162		163
164		165		166		167
168		169		170		171
172		173		174		175
176		177		178		179
180		181		182		183
184		185		186		187
188		189		190		191
192		193		194		195
196		197		198		199
200		201		202		203
204		205		206		207
208		209		210		211
212		213		214		215
216		217		218		219
220		221		222		223
224		225		226		227
228		229		230		231
232		233		234		235
236		237		238		239
240		241		242		243
244		245		246		247
248		249		250		251
252		253		254		255
256		257		258		259
260		261		262		263
264		265		266		267
268		269		270		271
272		273		274		275
276		277		278		279
280		281		282		283
284		285		286		287
288		289		290		291
292		293		294		295
296		297		298		299
300		301		302		303
304		305		306		307
308		309		310		311
312		313		314		315
316		317		318		319
320		321		322		323
324		325		326		327
328		329		330		331
332		333		334		335
336		337		338		339
340		341		342		343
344		345		346		347
348		349		350		351
352		353		354		355
356		357		358		359
360		361		362		363
364		365		366		367
368		369		370		371
372		373		374		375
376		377		378		379
380		381		382		383
384		385		386		387
388		389		390		391
392		393		394		395
396		397		398		399
400		401		402		403
404		405		406		407
408		409		410		411
412		413		414		415
416		417		418		419
420		421		422		423
424		425		426		427
428		429		430		431
432		433		434		435
436		437		438		439
440		441		442		443
444		445		446		447
448		449		450		451
452		453		454		455
456		457		458		459
460		461		462		463
464		465		466		467
468		469		470		471
472		473		474		475
476		477		478		479
480		481		482		483
484		485		486		487
488		489		490		491
492		493		494		495
496		497		498		499
500		501		502		503
504		505		506		507
508		509		510		511
512		513		514		515
516		517		518		519
520		521		522		523
524		525		526		527
528		529		530		531
532		533		534		535
536		537		538		539
540		541		542		543
544		545		546		547
548		549		550		551
552		553		554		555
556		557		558		559
560		561		562		563
564		565		566		567
568		569		570		571
572		573		574		575
576		577		578		579
580		581		582		583
584		585		586		587
588		589		590		591
592		593		594		595
596		597		598		599
600		601		602		603
604		605		606		607
608		609		610		611
612		613		614		615
616		617		618		619
620		621		622		623
624		625		626		627
628		629		630		631
632		633		634		635
636		637		638		639
640		641		642		643
644		645		646		647
648		649		650		651
652		653		654		655
656		657		658		659
660		661		662		663
664		665		666		667
668		669		670		671
672		673		674		675
676		677		678		679
680		681		682		683
684		685		686		687
688		689		690		691
692		693		694		695
696		697		698		699
700		701		702		703
704		705		706		707
708		709		710		711
712		713		714		715
716		717		718		719
720		721		722		723
724		725		726		727
728		729		730		731
732		733		734		735
736		737		738		739
740		741		742		743
744		745		746		747
748		749		750		751
752		753		754		755
756		757		758		759
760		761		762		763
764		765		766		767
768		769		770		771
772		773		774		775
776		777		778		779
780		781		782		783
784		785		786		787
788		789		790		791
792		793		794		795
796		797		798		799
800		801		802		803
804		805		806		807
808		809		810		811
812		813		814		815
816		817		818		819
820		821		822		823
824		825		826		827
828		829		830		831
832		833		834		835
836		837		838		839
840		841		842		843
844		845		846		847
848		849		850		851
852		853		854		855
856		857		858		859
860		861		862		863
864		865		866		867
868		869		870		871
872		873		874		875
876		877		878		879
880		881		882		883
884		885		886		887
888		889		890		891
892		893		894		895
896		897		898		899
900		901		902		903
904		905		906		907
908		909		910		911
912		913		914		915
916		917		918		919
920		921		922		923
924		925		926		927
928		929		930		931
932		933		934		935
936		937		938		939
940		941		942		943
944		945		9		

INDICATION

Axumin[®] (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
- Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Axumin Prescribing Information, also available at www.axumin.com.